# US 2013/0158064 A1 · Novel iso-ergoline derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0158064 A1
- Document ID: US20130158064A1
- Status: Published application
- Kind: A1
- Application number: 13/531,416
- Filed: 2012-06-22
- Published: 2013-06-20
- Earliest claimed: 2011-12-19
- Assignees: MAP Pharmaceuticals, Inc.
- Inventors: Jian Zhang; Robert O. Cook
- Web page: https://patentgrep.com/patent/US20130158064A1

## CPC

- C07D 457/12: Nitrogen atoms
- A61P 25/06: Antimigraine agents
- A61P 25/16: Anti-Parkinson drugs
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D 519/02: Ergot alkaloids of the cyclic peptide type
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are novel iso-ergoline derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1D and/or the 5-HT1Breceptor, without agonizing the 5-HT2B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the adrenergic alpha2A and/or the alpha2Breceptors using the compounds and compositions disclosed herein.

## Claims

### Claim 1

A compound of Formula (I) or (II):
or ion pairs, metabolites, polymorphs, salts, hydrates or solvates thereof, wherein:
R1 is hydrogen, (C1-C4) alkyl, substituted (C1-C4) alkyl or (C1-C4) alkyl substituted with one or more fluorine atoms;
R2 is alkyl, substituted alkyl, acyl, substituted acyl, halo, heteroalkyl, substituted heteroalkyl, —NO2, —N3, —OH, —S(O)kR100, —OR101, —NR102R103, —CONR104R105, —CO2R106 or —O2CR107;
R3 is hydrogen, (C1-C3) alkyl, (C1-C3) substituted alkyl or (C1-C3) alkyl substituted with one or more fluorine atoms;
R4 is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl, —OR108, —NR109R110,
R5 is (C1-C4) alkyl or (C1-C4) substituted alkyl;
R6 is hydrogen, (C1-C4) alkyl, substituted (C1-C4) alkyl, benzyl or substituted benzyl;
R7 is C1-C4) alkyl, substituted (C1-C4) alkyl, benzyl or substituted benzyl;
R8 is hydrogen, OH, ═O, (C1-C4) alkyl, (C1-C4) substituted alkyl, —CO2R114 or —CONR115R116;
R9 is hydrogen, OH, ═O, (C1-C4) alkyl, (C1-C4) substituted alkyl, —CO2R117 or —CONR118R119;
R10 is hydrogen, OH, ═O, (C1-C4) alkyl, (C1-C4) substituted alkyl, —CO2R120 or —CONR121R122;
R11 is hydrogen, (C1-C3) alkyl or (C1-C3) alkyl substituted with one or more fluorine atoms;
R12 is hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, —S(O)mR111 or —CONR112R113;
R100-R122 are independently hydrogen, alkyl, substituted alkyl, acyl, substituted acyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl;
m and k are independently 0, 1 or 2;
n is 0, 1, 2 or 3; and
provided that when R11 is hydrogen or (C1-C3) alkyl, R1 is (C1-C4) alkyl substituted with one or more fluorine atoms; and R109 and R110 are not substituted with fluorine unless R12 is acyl or substituted acyl.

### Claim 2 (depends on 1)

The compound of claim 1, having the structure:

### Claim 3 (depends on 1)

The compound of claim 1, having the structure:

### Claim 4 (depends on 1)

The compound of claim 1, having the structure:

### Claim 5 (depends on 1)

A composition comprising the compound of claim 1 and a vehicle.

### Claim 6 (depends on 1)

A method of treating and/or preventing migraine in a subject comprising administering to the subject in need thereof a therapeutically effective amount of the compound of claim 1.

### Claim 7 (depends on 5)

A method of treating and/or preventing migraine in a subject comprising administering to the subject in need thereof a therapeutically effective amount of the composition of claim 5.

### Claim 8 (depends on 1)

A method of treating and/or preventing Parkinson's disease in a subject comprising administering to the subject in need thereof a therapeutically effective amount of the compound of claim 1.

### Claim 9 (depends on 5)

A method of treating and/or preventing Parkinson's disease in a subject comprising administering to the subject in need thereof a therapeutically effective amount of the composition of claim 5.

### Claim 10 (depends on 1)

A method of agonizing the D2 receptor in a subject comprising administering to the subject in need thereof a therapeutically effective amount of the compound of claim 1.

### Claim 11 (depends on 1)

A method of agonizing the 5-HT1D receptor in a subject comprising administering to the subject in need thereof a therapeutically effective amount of the compound of claim 1.

### Claim 12 (depends on 1)

A method of agonizing the 5-HT1B receptor in a subject comprising administering to the subject in need thereof a therapeutically effective amount of the compound of claim 1.

### Claim 13 (depends on 1)

A method of selectively agonizing the 5-HT1D receptor over the 5-HT1B receptor in a subject comprising administering to the subject in need thereof a therapeutically effective amount of the compound of claim 1.

### Claim 14 (depends on 1)

A method of providing functional antagonist activity at the 5-HT2B receptor in a subject comprising administering to the subject in need thereof a therapeutically effective amount of the compound of claim 1.
